Skip to main content

What the FDA labels say about taking them together

Buprenorphine and carbamazepine

Buprenorphine's FDA label of June 5, 2026 names carbamazepine in its drug interactions section, and carbamazepine's label names buprenorphine too. The buprenorphine label: “The effects of co-administered CYP3A4 inducers on buprenorphine exposure in patients treated with BRIXADI have not been studied. Buprenorphine is metabolized to norbuprenorphine primarily by CYP3A4; …”

Check it at the source: the buprenorphine FDA label on DailyMed (effective June 5, 2026); the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation).

What does the buprenorphine label say about carbamazepine?

Buprenorphine label, drug interactions

CYP3A4 Inducers Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine, potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine. … sublingual tablets dosage reduction and monitor for signs of respiratory depression. Examples: Rifampin, carbamazepine, phenytoin

Brixadi label (Braeburn Inc., December 31, 2025), drug interactions

Clinical Impact: The effects of co-administered CYP3A4 inducers on buprenorphine exposure in patients treated with BRIXADI have not been studied. Buprenorphine is metabolized to norbuprenorphine primarily by CYP3A4; therefore, potential interactions may occur when BRIXADI is given concurrently with agents that affect CYP3A4 activity. … buprenorphine that permits more precise dose adjustments [see Clinical Pharmacology (12.3) ]. Rifampin, carbamazepine, phenytoin, phenobarbital Antiretrovirals: Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Source: FDA drug label (Brixadi, NDA210136), Braeburn Inc., effective December 31, 2025 (SPL set 5d8a8fd0-8619-422a-a664-d1d2e8970f48), via openFDA

Source: FDA drug label (Butrans, NDA021306), Knoa Pharma LLC, effective May 1, 2026 (SPL set 794aa355-66de-41b8-aedf-f2c40f6bc664), via openFDA

Source: FDA drug label (Sublocade, NDA209819), Indivior Inc., effective July 27, 2026 (SPL set 6189fb21-9432-45f8-8481-0bfaf3ccde95), via openFDA

Source: FDA drug label (Buprenorphine HCl), SpecGx LLC, effective June 5, 2026 (SPL set b60d514d-a88a-4fa2-a5b0-30ac29e04973), via openFDA; the full label on DailyMed

What does the carbamazepine label say about buprenorphine?

Carbatrol label (Takeda Pharmaceuticals America, Inc., August 17, 2026), drug interactions

Acetaminophen, albendazole, alprazolam, aprepitant, buprenorphine, apixaban (6), bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, corticosteroids (e.g. prednisolone, dexamethasone), cyclosporin, dabigatran (6), delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, edoxaban (6), eslicarbazepine, ethosuximide, everolimus, felbamate, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuximide, midazolam, mirtazapine, nefazodone, nortriptyline, olanzapine, oral and other hormonal contraceptives (2), oxcarbazepine, paliperidone, phenytoin (3), praziquantel, protease …

Source: FDA drug label (Carbatrol, NDA020712), Takeda Pharmaceuticals America, Inc., effective August 17, 2026 (SPL set bc03e499-5bac-4293-bff4-6864153a624d), via openFDA

Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

27Buprenorphine generic labelers
42Carbamazepine generic labelers
BuprenorphineCarbamazepine
Labeled forOpioid use disorder, PainBipolar disorder, Seizures and epilepsy
Boxed warningNoYes
Pharmacy cost (NADAC)$0.277 per tablet 2 mg tablet sl$0.119 per tablet 200 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?